Imricor and Philips launch interventional MR lab solution
Imricor Medical Systems announced the commercial launch of a combined interventional MR (iMR) lab solution developed with Philips, integrating Philips' 1.5T BlueSeal MR platform with Imricor's NorthStar, Advantage-MR and related systems plus single-use catheters and tools. The solution is available immediately in CE-marked markets, with select configurations in the United States now and additional US and other geography launches pending regulatory approvals. Management frames the launch as a scalable foundation for growth and expanded clinical use beyond cardiac electrophysiology, and Imricor will showcase the system at ESC Congress 2026 in Munich.
Combined iMR lab solution is available immediately in CE-marked markets
Context
Imricor and Philips have worked together since 2012 to develop joint technology. They now launched a combined iMR lab that is available in CE-marked markets. More configurations will follow as regulators approve them.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked